Whether you're sourcing suppliers or finding providers, start your journey with confidence today.
KPV (Lysine-Proline-Valine Tripeptide)
Also known as: Alpha-MSH C-Terminal Tripeptide, Lys-Pro-Val
Confidence
Updated 2026-03-18
KPV is a naturally occurring tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the potent anti-inflammatory properties of the parent hormone without melanocortin receptor activation (no tanning or hormonal effects). It has gained significant interest in functional medicine for gut inflammation, particularly inflammatory bowel disease.
Class
Anti-Inflammatory Peptide
Routes
Oral (capsule), Subcutaneous, Topical, Rectal (compounded)
Half-Life
Not formally established. Small tripeptide likely degraded rapidly in circulation (~minutes). Oral/colonic formulations may provide local gut exposure.
KPV enters cells and directly interacts with intracellular inflammatory signaling pathways. It inhibits NF-kB activation (master inflammatory transcription factor), reduces pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1beta), and decreases neutrophil infiltration. Uniquely, it achieves these effects through an intracellular mechanism that does not require melanocortin receptor binding, allowing anti-inflammatory action without melanocortin side effects.
Half-Life
Not formally established. Small tripeptide likely degraded rapidly in circulation (~minutes). Oral/colonic formulations may provide local gut exposure.
Bioavailability
Not established. Oral bioavailability likely very low for systemic absorption. Targeted intestinal delivery may provide local colonic concentrations.
No approved indications. Research: inflammatory bowel disease (UC, Crohn's), gut inflammation, skin inflammation, wound healing.
Preclinical studies demonstrate potent anti-inflammatory effects in colitis models (both chemical and genetic). KPV-loaded nanoparticles showed targeted colonic delivery and inflammation reduction in mice. Minimal human clinical data — use in IBD patients is based on extrapolation from preclinical work and anecdotal clinical experience in functional medicine. No RCTs in humans.
Human Studies
2
Animal Studies
20
Generally considered low-risk given its endogenous origin (fragment of alpha-MSH). No significant adverse effects reported in preclinical studies. Minimal human safety data. Theoretical immunosuppressive risk with chronic use. No known serious adverse events.
Investigational. Available through compounding pharmacies and research suppliers. Used in functional medicine protocols for gut health. No regulatory pathway active.
Drug Interactions: Theoretical interactions with immunosuppressants used in IBD (biologics, steroids). Monitoring: Inflammatory markers (CRP, calprotectin), symptom assessment for GI use. Research Gaps: No human RCTs. Oral bioavailability and optimal delivery method undefined. Dose-response not established in humans.
Oral capsule (research/clinical context)
Common Range
200–500 mcg/day (oral); 200–500 mcg (subcutaneous)
Timing
With or without food
Frequency
Once to twice daily
Cycling
4–12 weeks in clinical protocols
Important Note
NOT FDA-approved. Primarily used in functional medicine for gut inflammation. Evidence base is largely preclinical. Research context only.
Connect with a verified provider offering KPV therapy near you.
Tissue Repair & Regeneration
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It has generated extraordinary interest for its broad cytoprotective and regenerative effects observed in preclinical studies across virtually every organ system studied. Despite this promise, it remains one of the most controversial peptides due to the near-complete absence of human clinical trial data.
Antimicrobial Peptide
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid peptide cleaved from the precursor protein hCAP-18. It serves as a critical component of innate immunity with broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses. Beyond direct antimicrobial action, it modulates inflammation, wound healing, and immune cell recruitment.
Immune Modulator
Thymosin alpha-1 is a 28-amino acid peptide originally isolated from thymic tissue. It is approved in over 35 countries (not the US) under the brand name Zadaxin for immune modulation in hepatitis B and as an adjunct to chemotherapy. It represents a unique case in peptide regulation — internationally validated but caught in US regulatory limbo.
Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting, stopping, or modifying any peptide therapy. PeptideSupplierMatch does not prescribe, sell, or distribute peptides.
Whether you're sourcing peptides for your business or looking for providers near you, we can help.